This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Intellia's (NTLA) NTLA-5001 Gets FDA Orphan Drug Tag for AML
by Zacks Equity Research
Intellia's (NTLA) investigational gene-editing therapy, NTLA-5001, gets an Orphan Drug tag from the FDA for AML.
Intellia (NTLA) Q4 Loss Wider Than Expected, Revenues Up Y/Y
by Zacks Equity Research
Intellia Therapeutics (NTLA) reports wider-than-expected Q4 loss. Nonetheless, revenues beat estimates.
Intellia Therapeutics, Inc. (NTLA) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Intellia Therapeutics, Inc. (NTLA) delivered earnings and revenue surprises of -19.78% and 33.35%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Should iShares Russell 2000 Growth ETF (IWO) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for IWO
Earnings Preview: Intellia Therapeutics, Inc. (NTLA) Q4 Earnings Expected to Decline
by Zacks Equity Research
Intellia Therapeutics, Inc. (NTLA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Intellia (NTLA) Up on Deal With ONK for Cancer Therapies
by Zacks Equity Research
Intellia (NTLA) partners with ONK Therapeutics. The collaboration utilises their respective proprietary platforms to develop allogeneic CRISPR-based NK cell therapies for the treatment of cancer.
Should Vanguard Russell 2000 Growth ETF (VTWG) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for VTWG
Editas (EDIT) Focuses on Developing Gene-Editing Eye Drug
by Zacks Equity Research
Editas' (EDIT) lead pipeline candidate, EDIT-101, which employs CRISPR gene editing to treat LCA10, holds potential. Dependence on partners for collaboration revenues a woe.
Intellia (NTLA) Inks Deal With Kyverna for Autoimmune Diseases
by Zacks Equity Research
Intellia (NTLA) inks a licensing and collaboration deal with Kyverna Therapeutics for developing an allogeneic CAR T-cell therapy for autoimmune diseases.
Intellia's (NTLA) CRISPR Therapies Show Promise Amid Competition
by Zacks Equity Research
While Intellia's (NTLA) pipeline is in early-stage clinical studies, its development is progressing well. Collaborations are a primary source of revenues in the absence of a marketed product.
5 Biotech Stocks That More Than Doubled This Year
by Ekta Bagri
The biotech sector has been in focus through 2021 as vaccine makers like Moderna (MRNA) BioNTech (BNTX), and other companies like Dynavax (DVAX), Prothena (PRTA) and Intellia (NTLA) put up an exemplary performance.
Should iShares Russell 2000 Growth ETF (IWO) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for IWO
Should Vanguard Russell 2000 Growth ETF (VTWG) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for VTWG
Intellia (NTLA) Begins Dosing in Hereditary Angioedema Study
by Zacks Equity Research
Intellia (NTLA) doses the first patient in a phase I/II study to evaluate NTLA-2002 as a single-dose therapy for preventing attacks in patients having hereditary angioedema.
Intellia Therapeutics, Inc. (NTLA) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Intellia Therapeutics, Inc. (NTLA) delivered earnings and revenue surprises of -14.12% and -16.24%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for XBI
Should You Invest in the SPDR S&P Biotech ETF (XBI)?
by Zacks Equity Research
Sector ETF report for XBI
Earnings Preview: Intellia Therapeutics, Inc. (NTLA) Q3 Earnings Expected to Decline
by Zacks Equity Research
Intellia Therapeutics, Inc. (NTLA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Intellia's (NTLA) CRISPR Therapy Gets FDA's Orphan Drug Tag
by Zacks Equity Research
Intellia's (NTLA) investigational gene-editing therapy, NTLA-2001, gets Orphan Drug tag from the FDA for ATTR amyloidosis.
Should iShares Russell 2000 Growth ETF (IWO) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for IWO
Editas (EDIT) Focuses on Developing Gene Drug for Eye Disease
by Zacks Equity Research
Editas (EDIT) progresses well with the development of its lead candidate, EDIT-101, to treat LCA10, a rare genetic illness that causes blindness. Dependence on partners for revenues is a concern.
Editas (EDIT) Down on Initial Data From Eye Disease Study
by Zacks Equity Research
Editas (EDIT) posts initial data from the phase I/II BRILLIANCE study evaluating EDIT-101 for treating Leber congenital amaurosis 10, an inherited form of blindness.
New Strong Sell Stocks for August 24th
by Zacks Equity Research
BGS, FTHM, NTLA, LEVL, and ELOX have been added to the Zacks Rank #5 (Strong Sell) List on August 24, 2021
Editas (EDIT) Up More Than 70% in Past 3 Months: Here's Why
by Zacks Equity Research
Editas' (EDIT) lead candidate, EDIT-101, which employs CRISPR gene editing to treat LCA10, holds potential. The company is also developing EDIT-301 for treating hematologic diseases.
How Are Genomics ETFs Responding to Q2 Earnings?
by Sweta Jaiswal, FRM
Let's take a look at some big genomics earnings releases to see if these will impact ETFs exposed to the space.